Search Follow us


EdisonTV | Pharmaceutical & healthcare | 17/01/2018

Executive Interview - NeuroVive Pharmaceutical (Part 2)

NeuroVive is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the progress KL1333 has made over the past month – receiving orphan drug designation in Europe and the status of the first clinical trial.

Please click here to re-watch Part 1, or here to watch Part 3.

» overview & latest research